Compare Citius Pharmaceuticals Inc (CTXR) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Humana Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Humana Inc trades at $431.03 (market cap $46.49B). The key difference: Humana Inc is far larger — about 3413.4× Citius Pharmaceuticals Inc's market cap, and Humana Inc pays a 0.91% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Humana Inc for 51 Days on average.
| CTXR | HUM | |
|---|---|---|
Market Cap | $13.62M | $46.49B |
Volume | 132,438 | 2,567,704 |
Sector | Health | Health |
52-Week High | $1.82 | $409.85 |
52-Week Low | $0.48 | $163.67 |
Typical Hold Time | 17 Days | 51 Days |
Enterprise Value | $3.79M | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Humana (HUM) trades at $431.03, up 8.71% over the past day, reflecting strong momentum following a Barclays upgrade and positive earnings beats. The stock exhibits a bullish technical trend, with support at $378 and resistance at $394. Revenue has grown steadily from $92.9B in 2022 to $129.7B in 2025, though net income margins have compressed to 0.88%. Analyst consensus is a Buy with a $457.05 price target, and recent news highlights corporate initiatives and institutional investments.
The outlook for HUM is cautiously optimistic, driven by revenue growth and analyst support, but risks include margin pressure and regulatory scrutiny. Investment opportunity lies in execution of Medicare Advantage strategies, while key risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder notices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
